Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-Guanidino-4-(N-nitro-benzoylamino-L-leucyl-L-prolylamino)butane is a synthetic small molecule dipeptide derivative, structurally related to amino acids leucine and proline, with a guanidinium group and a nitrobenzoyl moiety. It is classified as an experimental compound and has not been approved for clinical use. The compound has been studied in the context of protein interactions, notably as a ligand in structural studies involving prothrombin/thrombin, suggesting it may act as an inhibitor or modulator of serine proteases involved in blood coagulation. However, no specific mechanism of action or therapeutic indication has been established for this molecule[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-guanidino-4-(N-nitro-benzoylamino-L-leucyl-L-prolylamino)butane.